The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

This article summarizes the expert discussion on the management of hepatocellular carcinoma (HCC), which took place during the 10th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, June 2008. A multidisciplinary approach to a patient with HCC is essential, to guarantee optimal diagnosis and staging, planning of surgical options and selection of embolisation strategies or systemic therapies. In many patients, the underlying cirrhosis represents a challenge and determines therapeutic options. There is now robust evidence in favour of systemic therapy with sorafenib in patients with advanced HCC with preserved liver function. Those involved in the care for patients with HCC should be encouraged to participate in well-designed clinical trials, to increase evidence-based knowledge and to make further progress.

[1]  Tae Hyun Kim,et al.  A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[2]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[3]  X. Paoletti,et al.  Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Makuuchi,et al.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. , 2008, Gastroenterology.

[5]  Eva Pagano,et al.  Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial , 2008, Scandinavian journal of gastroenterology.

[6]  T. Roskams,et al.  Nuclear β‐catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy , 2007, Histopathology.

[7]  Laura Crocetti,et al.  Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US , 2007, European radiology.

[8]  A. Benson,et al.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis , 2007, Hepatology.

[9]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[10]  A. Burroughs,et al.  Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. , 2007, Cancer treatment reviews.

[11]  G. Giannelli,et al.  New frontiers in biomarkers for hepatocellular carcinoma. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  Mi-Suk Park,et al.  Newly Developed Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: MR Imaging Findings Before the Diagnosis of HCC , 2006, Journal of computer assisted tomography.

[13]  E. Lesaffre,et al.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin , 2006, Histopathology.

[14]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[16]  Guy Marchal,et al.  Local Recurrence After Hepatic Radiofrequency Coagulation: Multivariate Meta-Analysis and Review of Contributing Factors , 2005, Annals of surgery.

[17]  M. Stockler,et al.  Use of tamoxifen in advanced‐stage hepatocellular carcinoma , 2005, Cancer.

[18]  L. Mariani,et al.  Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation: A Prospective Study , 2004, Annals of surgery.

[19]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[20]  L. Bolondi,et al.  Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. , 2004, Journal of hepatology.

[21]  Katsuyoshi Ito,et al.  Cirrhosis or chronic hepatitis: evaluation of small (, 2003, Radiology.

[22]  S. Hussain,et al.  Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. , 2002, Radiographics : a review publication of the Radiological Society of North America, Inc.

[23]  T. Roskams,et al.  Focal lesions in cirrhotic explant livers: Pathological evaluation and accuracy of pretransplantation imaging examinations , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[25]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[26]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[27]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[28]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[29]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[30]  H. Popper.  American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury , 1960 .

[31]  L. Mariani,et al.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.

[32]  S. Schoenberg,et al.  Dual breath-hold magnetic resonance cine evaluation of global and regional cardiac function , 2006, European Radiology.

[33]  Carlo Bartolozzi,et al.  Imaging diagnosis. , 2005, Seminars in liver disease.

[34]  T. Roskams,et al.  Early hepatocellular carcinoma and dysplastic nodules. , 2005, Seminars in liver disease.

[35]  C. Bartolozzi,et al.  Magnetic resonance imaging of liver tumors. , 2004, Journal of hepatology.

[36]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.